Our current study revealed an aberrant upregulation of SHCBP1 in NSCLC and identified a correlation of upregulation of total as well as nuclear SHCBP1 with unfavorable outcomes for NSCLC patients, suggesting a potentially promising use of SHCBP1 as a clinically indicative biomarker for NSCLC prognosis. This evidence concerns the gene SHCBP1 and non-small cell lung carcinoma.